Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00477971
First received: May 23, 2007
Last updated: March 4, 2014
Last verified: March 2014

May 23, 2007
March 4, 2014
October 2005
July 2012   (final data collection date for primary outcome measure)
Hematologic response rate [ Time Frame: 10 years ] [ Designated as safety issue: No ]
Hematologic response rate
Complete list of historical versions of study NCT00477971 on ClinicalTrials.gov Archive Site
  • Toxicity [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
  • Overall survival [ Time Frame: 10 years ] [ Designated as safety issue: No ]
  • Organ response to treatment [ Time Frame: 10 years ] [ Designated as safety issue: No ]
  • Patient-reported outcomes [ Time Frame: 10 years ] [ Designated as safety issue: No ]
  • Toxicity
  • Overall survival
  • Organ response to treatment
  • Patient-reported outcomes
Not Provided
Not Provided
 
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL)

RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Having an autologous stem cell transplant to replace the blood-forming cells destroyed by chemotherapy, allows higher doses of chemotherapy to be given so that more plasma cells are killed. By reducing the number of plasma cells, the disease may progress more slowly. It is not yet known whether combination chemotherapy is more effective than chemotherapy followed by an autologous stem cell transplant in treating primary systemic amyloidosis.

PURPOSE: This randomized phase III trial is studying the side effects and how well giving low-dose melphalan together with dexamethasone works compared with high-dose melphalan followed by an autologous stem cell transplant in treating patients with primary systemic amyloidosis.

OBJECTIVES:

Primary

  • Compare hematologic response rate in patients with primary systemic amyloidosis treated with conventional chemotherapy comprising low-dose melphalan and dexamethasone vs high-dose melphalan followed by autologous stem cell transplantation.
  • Compare the toxicity of these regimens in these patients.

Secondary

  • Compare the overall and progression-free survival of patients treated with these regimens.
  • Compare the regression of organ involvement in patients treated with these regimens.
  • Compare the duration of response in patients treated with these regimens.
  • Correlate clonal burden and time to in vitro amyloid formation with clinical outcomes in patients treated with these regimens.
  • Compare quality of life of patients treated with these regimens.
  • Compare the information-seeking behavior in patients treated with these regimens.

OUTLINE: This is a comprehensive cohort study comprising a randomized option and a nonrandomized option. Patients consenting to randomization are stratified by risk group (high vs low) and ECOG performance status (0-1 vs 2). They are then randomized to 1 of 2 treatment arms. Patients not consenting to randomization choose their treatment arm.

  • Arm I: Patients receive low-dose melphalan IV over 15-30 minutes on day 1 or orally once daily on days 1-7 and oral dexamethasone on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive filgrastim (G-CSF) on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan IV over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.

Blood and bone marrow samples are collected at baseline. Samples are examined by PCR, cDNA, and nucleotide sequence analysis to determine VH and VL gene families and carrier status. Urine is collected at baseline and analyzed for light-chain protein levels by exclusion chromatography.

Quality of life is assessed at baseline, at months 3, 9, and 12, at completion of study treatment, and then every 6 months for up to 5 years.

After completion of study treatment, patients are followed every 6 months for up to 10 years.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma and Plasma Cell Neoplasm
  • Biological: filgrastim
    No administration information given
  • Drug: dexamethasone
    Given orally
  • Drug: melphalan
    Given IV or orally
  • Procedure: autologous hematopoietic stem cell transplantation
    Given on day 0
  • Active Comparator: Arm I

    Patients receive low-dose melphalan IV over 15-30 minutes on day

    1 or orally once daily on days 1-7 and oral dexamethasone on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses.

    Study treatment beyond one year is not allowed.

    Interventions:
    • Drug: dexamethasone
    • Drug: melphalan
  • Experimental: Arm II
    Patients receive filgrastim (G-CSF) on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan IV over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.
    Interventions:
    • Biological: filgrastim
    • Drug: melphalan
    • Procedure: autologous hematopoietic stem cell transplantation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
152
December 2014
July 2012   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed primary systemic amyloidosis

    • Amyloid light-chain (AL) disease
  • Monoclonal protein by immunoelectrophoresis or immunofixation of the serum or urine OR abnormal free light-chain ratio
  • The following amyloid syndromes* are allowed:

    • Amyloid hepatomegaly
    • Cardiomyopathy
    • Proteinuria
    • Peripheral or autonomic neuropathy
    • Soft tissue involvement including the tongue, submandibular tissues, and vascular claudication
    • Diffuse interstitial pulmonary AL disease allowed if pulmonary function is adequate to allow safe transplantation NOTE: *Presence of amyloid deposits in a plasmacytoma or in bone marrow vessels in an asymptomatic patient does not constitute an amyloid syndrome
  • No secondary or familial amyloidosis
  • No multiple myeloma with lytic or destructive bone lesions or myeloma cast nephropathy
  • No multiple myeloma with > 30% plasma cells in the bone marrow
  • No amyloidosis manifested only by carpal tunnel syndrome or purpura

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Platelet count ≥ 100,000/mm³
  • Bilirubin ≤ 2.0 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 6 times ULN
  • Creatinine ≤ 3.0 mg/dL
  • No NYHA class IV heart disease
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No uncontrolled infection
  • No HIV positivity

PRIOR CONCURRENT THERAPY:

  • Prior alkylating agents, immunosuppressive drugs, or steroids allowed provided they were given for < 1 month

    • Therapeutic steroid doses of ≤ 15 mg per day (or equivalent) allowed at discretion of physician
  • No concurrent participation in another clinical trial involving a pharmacologic agent
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00477971
CDR0000546745, P30CA015083, MC0482, 1691-05, NCI-2009-01329
Yes
Morie Abraham Gertz, Mayo Clinic Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
Study Chair: Morie A. Gertz, MD Mayo Clinic
Mayo Clinic
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP